Aktiesnakken — August 2012
-
heller opgradere receptionisten til at lave noget let drugdiscovery
-
han reddet så meget vores popo ved den første aftale med GSK
-
jeg fatter stadig ikke hvordan han kunne lave den aftale
-
Nej den er godt nok kæmpe stor. Men der er jo heller ingen tvivl om at GSK virker tror på Arzerra
-
gad godt vide om de er med i opløbet på Dara
-
jo de fik den til at stige 20% på en enkelt dag
-
tror GSK er med på banen, men håber alligevel det bliver en anden, eventuelt Merck. Vil gerne have det lidt spredt ud
-
Dr Samir Devani – a registered pharmacist by training with a PhD in molecular drug design, Samir has 13 years experience as a healthcare analyst. His primary focus has been on drug development, drug delivery and specialty pharmaceutical companies in Europe, although during his time at JP Morgan he spent a significant amount of time additionally analyzing US companies. His main role has been to provide investment advice on companies in these areas to institutional fund managers.
-
Analytikerne der dækker Genmab for Nomura
-
jeg vil hellere have han har gode overtalelsesevner
-
nåå north media, må godt lige komme nu
-
Hvorfor det solsen?
-
http://clinicaltrials.gov/ct2/show/study/NCT01457924?term=arzerra+AND+sc&rank=2&show_locs=Y#locn 36 centre åben for patienter - fuld knald på
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind